cl-075 and resiquimod

Chemokines have been shown to play immune-modulatory functions unrelated to steering cell migration. CXCL4 is a chemokine abundantly produced by activated platelets and immune cells. Increased levels of circulating CXCL4 are associated with immune-mediated conditions, including systemic sclerosis. Considering the central role of dendritic cells (DCs) in immune activation, in this article we addressed the effect of CXCL4 on the phenotype and function of monocyte-derived DCs (moDCs). To this end, we compared innate and adaptive immune responses of moDCs with those that were differentiated in the presence of CXCL4. Already prior to TLR- or Ag-specific stimulation, CXCL4-moDCs displayed a more matured phenotype. We found that CXCL4 exposure can sensitize moDCs for TLR-ligand responsiveness, as illustrated by a dramatic upregulation of CD83, CD86, and MHC class I in response to TLR3 and TLR7/8-agonists. Also, we observed a markedly increased secretion of IL-12 and TNF-α by CXCL4-moDCs exclusively upon stimulation with polyinosinic-polycytidylic acid, R848, and CL075 ligands. Next, we analyzed the effect of CXCL4 in modulating DC-mediated T cell activation. CXCL4-moDCs strongly potentiated proliferation of autologous CD4

Topics: Antigens, CD; B7-2 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; CD83 Antigen; Cell Differentiation; Cells, Cultured; Coculture Techniques; Dendritic Cells; Escherichia coli; Escherichia coli Infections; Genes, MHC Class I; Humans; Imidazoles; Immunoglobulins; Interleukin-12; Lymphocyte Activation; Membrane Glycoproteins; Phenotype; Platelet Factor 4; Poly I-C; Quinolines; Thiazoles; Tumor Necrosis Factor-alpha

In the absence of an experimental bTLR8 structure, recent studies have called attention to the fact that bTLR8 can also be activated by hTLR7/hTLR8 agonist, such as antiviral imidazoquinoline derivatives of resiquimod (R848) and imiquimod (R837) as well as some guanine nucleotide analogs with a scaffold structure related to the nucleic acids of ssRNA virus. In particular, the known small agonists (namely CL075, CL097 and R848) have been targeted to determine distinguishable deciding factors in complex with dimeric bTLR8-ECDs in comparison to ligand-induced activated hTLR8-ECDs. According to basic knowledge, the deciding eligibility criteria can be subsequently applied in our bTLR8 model to characterize the 3D-arrangement of chemical features (pharmacophore) and to investigate the distinct restrictions affecting species-specificity on dual TLR7/TLR8 small agonists suggested in previous works. Despite the lack of extensive structural biology studies regarding the interaction of bTLR8-ECDs with the agonists, our complex models of bTLR8-ECDs and the known agonists were applied to identify the deciding factors required for the interactions from agonist-based and (bTLR8-agonist complexes) structure-based pharmacophores. These pharmacophore constraints impose their essential chemical features to active bTLR8 receptors. The characterized pharmacophores all were employed in the virtual screening of candidates with a further acting factor of calf immune enhancer. Two hits were suggested as satisfying all decision factors to identify a potent bTLR8-specific agent with novel scaffolds dissimilar to imidazoquinoline analogues lacking overall homogeneity.

Topics: Amino Acid Sequence; Aminoquinolines; Animals; Antiviral Agents; Binding Sites; Cattle; Diarrhea Virus 1, Bovine Viral; Drug Design; Humans; Imidazoles; Imiquimod; Molecular Docking Simulation; Phylogeny; Protein Binding; Protein Domains; Protein Structure, Secondary; Quinolines; Sequence Alignment; Species Specificity; Structural Homology, Protein; Thiazoles; Toll-Like Receptor 8; Viral Nonstructural Proteins

FcγRs are critical mediators of mAb cancer therapies, because they drive cytotoxic processes upon binding of effector cells to opsonized targets. Along with NK cells, monocytes are also known to destroy Ab-coated targets via Ab-dependent cellular cytotoxicity (ADCC). However, the precise mechanisms by which monocytes carry out this function have remained elusive. In this article, we show that human monocytes produce the protease granzyme B upon both FcγR and TLR8 activation. Treatment with TLR8 agonists elicited granzyme B and also enhanced FcγR-mediated granzyme B production in an additive fashion. Furthermore, monocyte-mediated ADCC against cetuximab-coated tumor targets was enhanced by TLR8 agonist treatment, and this enhancement of ADCC required granzyme B. Hence we have identified granzyme B as an important mediator of FcγR function in human monocytes and have uncovered another mechanism by which TLR8 agonists may enhance FcγR-based therapies.

Topics: Amino Acid Chloromethyl Ketones; Angiotensinogen; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Blotting, Western; Cells, Cultured; Cetuximab; Cluster Analysis; Dose-Response Relationship, Drug; Granzymes; Humans; Imidazoles; Interleukin-2; Monocytes; NF-kappa B; Oligonucleotide Array Sequence Analysis; Perforin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Time Factors; Toll-Like Receptor 8; Transcriptome

Newborns display distinct immune responses that contribute to susceptibility to infection and reduced vaccine responses. Toll-like receptor (TLR) agonists may serve as vaccine adjuvants, when given individually or in combination, but responses of neonatal leukocytes to many TLR agonists are diminished. TLR8 agonists are more effective than other TLR agonists in activating human neonatal leukocytes in vitro, but little is known about whether different TLR8 agonists may distinctly activate neonatal leukocytes. We characterized the in vitro immuno-stimulatory activities of a novel benzazepine TLR8 agonist, VTX-294, in comparison to imidazoquinolines that activate TLR8 (R-848; (TLR7/8) CL075; (TLR8/7)), with respect to activation of human newborn and adult leukocytes. Effects of VTX-294 and R-848 in combination with monophosphoryl lipid A (MPLA; TLR4) were also assessed.. TLR agonist specificity was assessed using TLR-transfected HEK293 cells expressing a NF-κB reporter gene. TLR agonist-induced cytokine production was measured in human newborn cord and adult peripheral blood using ELISA and multiplex assays. Newborn and adult monocytes were differentiated into monocyte-derived dendritic cells (MoDCs) and TLR agonist-induced activation assessed by cytokine production (ELISA) and co-stimulatory molecule expression (flow cytometry).. VTX-294 was ≈ 100x more active on TLR8- than TLR7-transfected HEK cells (EC50, ≈ 50 nM vs. ≈ 5700 nM). VTX-294-induced TNF and IL-1β production were comparable in newborn cord and adult peripheral blood, while VTX-294 was 1 log more potent in inducing TNF and IL-1β production than MPLA, R848 or CL075. Combination of VTX-294 and MPLA induced greater blood TNF and IL-1β responses than combination of R-848 and MPLA. VTX-294 also potently induced expression of cytokines and co-stimulatory molecules HLA-DR and CD86 in human newborn MoDCs.. VTX-294 is a novel ultra-potent TLR8 agonist that activates newborn and adult leukocytes and is a candidate vaccine adjuvant in both early life and adulthood.

Topics: Adult; Analysis of Variance; Benzazepines; Dendritic Cells; Flow Cytometry; HEK293 Cells; Humans; Imidazoles; Infant, Newborn; Leukocytes; Lipid A; Quinolines; Thiazoles; Toll-Like Receptor 8

Toll-like receptor 7 (TLR7) and TLR8 recognize single-stranded RNA and initiate innate immune responses. Several synthetic agonists of TLR7-TLR8 display novel therapeutic potential; however, the molecular basis for ligand recognition and activation of signaling by TLR7 or TLR8 is largely unknown. In this study, the crystal structures of unliganded and ligand-induced activated human TLR8 dimers were elucidated. Ligand recognition was mediated by a dimerization interface formed by two protomers. Upon ligand stimulation, the TLR8 dimer was reorganized such that the two C termini were brought into proximity. The loop between leucine-rich repeat 14 (LRR14) and LRR15 was cleaved; however, the N- and C-terminal halves remained associated and contributed to ligand recognition and dimerization. Thus, ligand binding induces reorganization of the TLR8 dimer, which enables downstream signaling processes.

Topics: Amino Acid Sequence; Crystallography, X-Ray; Humans; Hydrogen Bonding; Imidazoles; Ligands; Models, Molecular; Molecular Sequence Data; Mutant Proteins; Protein Binding; Protein Conformation; Protein Multimerization; Protein Structure, Secondary; Protein Structure, Tertiary; Quinolines; Signal Transduction; Thiazoles; Toll-Like Receptor 8

In this paper, we describe a new method for preparation of human dendritic cells (DCs) that secrete bioactive IL-12(p70) using synthetic immunostimulatory compounds as TLR7/8 agonists. Monocyte-derived DCs were generated using a procedure that provided mature cells within 3 d. Several maturation mixtures that contained various cytokines, IFN-gamma, different TLR agonists, and PGE(2) were compared for impact on cell recovery, phenotype, cytokine secretion, migration, and lymphocyte activation. Mixtures that included the TLR7/8 agonists R848 or CL075, combined with the TLR3 agonist polyinosinic:polycytidylic acid, yielded 3-d mature DCs that secreted high levels of IL-12(p70), showed strong chemotaxis to CCR7 ligands, and had a positive costimulatory potential. They also had excellent capacity to activate NK cells, effectively polarized CD4(+) and CD8(+) T cells to secrete IFN-gamma and to induce T cell-mediated cytotoxic function. Thereby, mature DCs prepared within 3 d using such maturation mixtures displayed optimal functions required for vaccine development.

Topics: Adjuvants, Immunologic; Cancer Vaccines; Cell Differentiation; Cell Movement; Cell Polarity; Cells, Cultured; Coculture Techniques; Cytokines; Dendritic Cells; Humans; Imidazoles; Immunotherapy, Adoptive; Interferon-gamma; Killer Cells, Natural; Ligands; Lymphocyte Activation; Poly I-C; Quinolines; T-Lymphocytes, Cytotoxic; Th1 Cells; Thiazoles; Toll-Like Receptor 3; Toll-Like Receptor 7; Toll-Like Receptor 8

We previously reported that synthetic or natural Toll-like receptor (TLR) 7/8 agonists present within dead cells enhanced cell-associated antigen presentation both in vitro and in vivo. Here, we investigated the immunopotency of different chemically synthesized TLR7/8 agonists, Resiquimod, Gardiquimod, CL075, and CL097, on HBsAg immunogenicity. These agonists stimulated inflammatory monocyte-derived cells to become potent antigen-presenting dendritic cells (DCs), which augmented HBsAg specific T cell proliferation after they were conditioned with HBsAg. The TLR8 agonist CL075 and the TLR7/8 dual agonist CL097 showed more potent effects than the TLR7 agonist. Compared with alum adjuvant, when HBsAg mixed with CL075 was injected intramuscularly into mice, more monocyte-derived DCs carried antigens into draining lymph nodes and spleens. Specific Abs, particularly IgG2a, were significantly increased, and more IL-5 and IFN-gamma were produced by splenocytes and intrahepatic immunocytes in mice that received HBsAg mixed with CL075 and CL097. These results suggest that TLR8 agonists are good candidates to enhance recombinant HBsAg immunogenicity to induce specific humoral and cellular immune responses.

Topics: Alum Compounds; Aminoquinolines; Animals; Antibodies, Viral; Antigen-Presenting Cells; Cell Differentiation; Cells, Cultured; Dendritic Cells; Hepatitis B Surface Antigens; Humans; Imidazoles; Immunoglobulin G; Interferon-gamma; Interleukin-5; Leukocytes, Mononuclear; Mice; Mice, Inbred C57BL; Quinolines; Spleen; Thiazoles; Toll-Like Receptor 7; Toll-Like Receptor 8